small lymphocytic lymphoma

November 12, 2019

Janssen Requests FDA Approval of Imbruvica-rituximab Combo for First-line Treatment of CLL/SLL

News

Janssen is seeking approval from the U.S. Food and Drug Administration (FDA) for a combination of Imbruvica (ibrutinib) with rituximab to be used as a first-line treatment for people with ... Read more

October 25, 2019

Durable Responses Seen to ME-401 in Advanced Follicular Lymphoma and CLL/SLL Patients in Ongoing Trial

News

MEI Pharma’s experimental compound ME-401 reduced tumor burden in 78% of patients with relapsed or refractory follicular lymphoma and in 89% of those with relapsed or refractory chronic lymphocytic leukemia or ... Read more

October 16, 2018

Publication of Phase 3 Trial Results Supports FDA Approval of Copiktra, Verastem Announces

News

Copiktra (duvelisib) monotherapy may be an effective and safe treatment option for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to results from a Phase 3 ... Read more

January 2, 2018

Verastem to Seek FDA Approval for Duvelisib to Treat SLL and CLL After Consistently Positive Trial Results

News

Verastem‘s duvelisib significantly delays disease progression or death in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to Phase 3 trial results. The trial, called ... Read more

September 7, 2017

Verastem, with Phase 3 Results, to Request FDA Approve Oral Duvelisib to Treat Advanced CLL and SLL

News

Verastem’s duvelisib was seen to outperform Arzerra (ofatumumab) in a Phase 3 trial of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the company announced. ... Read more

July 10, 2017July 10, 2017

Potential Oral Therapy for Indolent Non-Hodgkin’s Lymphoma, Duvelisib, Shows Efficacy in Phase 2 Trial

News

An investigative oral therapy, duvelisib, was effective in treating indolent non-Hodgkin’s lymphoma among patients who did not respond to Rituxan (rituximab) and chemotherapy or radioimmunotherapy, according to results from a Phase ... Read more

June 20, 2016June 20, 2016

Phase 2 Study of Candidate for Refractory Indolent Non-Hodgkin Lymphoma Patients So-So

News

Infinity Pharmaceuticals recently announced that its Phase 2 clinical trial Dynamo evaluating the efficacy and safety of duvelisib in patients with refractory indolent non-Hodgkin lymphoma (iNHL) met its primary endpoint but ... Read more

June 8, 2016June 8, 2016

ASCO 2016 – AbbVie’s Imbruvica Phase 3 Trials in Leukemia and Lymphoma Patients Show Long-Term Favorable Responses

News

AbbVie has just presented long-term data on Imbruvica (ibrutinib) effects in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), revealing its therapeutic potential in these diseases. The ... Read more

May 13, 2016May 13, 2016

FDA Expands Label for Imbruvica (ibrutinib), a Lymphoma Therapy, to Include Improved Survival and Safety

News

The U.S. Food and Drug Administration (FDA) recently approved an expansion to prescribing information for the kinase inhibitor Imbruvica (ibrutinib), based on improved survival, safety, and efficacy data from studies in people with chronic ... Read more